The curious case of the BioNTech priority review voucher

Earlier this week, the FDA fully approved Moderna’s Covid-19 vaccine, and with that approval, the company was awarded what is almost certainly a lucrative priority review voucher.

The vouchers can be used for a priority review of a new drug, offering a short cut to an FDA decision, or can...

Click to view original post